AnaptysBio, Inc. (ANAB) Rating Lowered to Hold at Zacks Investment Research
AnaptysBio, Inc. (NASDAQ:ANAB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
Several other research analysts also recently issued reports on ANAB. Robert W. Baird assumed coverage on shares of AnaptysBio in a research note on Monday, July 10th. They issued an “outperform” rating and a $36.00 target price on the stock. Credit Suisse Group increased their price objective on shares of AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, August 25th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. AnaptysBio currently has an average rating of “Buy” and a consensus target price of $35.00.
Shares of AnaptysBio (ANAB) traded up 3.87% during trading on Wednesday, reaching $30.56. 347,380 shares of the company traded hands. The firm’s 50 day moving average is $24.20 and its 200-day moving average is $24.95. The stock’s market capitalization is $621.65 million. AnaptysBio has a 12-month low of $15.17 and a 12-month high of $31.00.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.29. The business had revenue of $7 million during the quarter, compared to analysts’ expectations of $3.45 million. On average, equities research analysts anticipate that AnaptysBio will post ($1.96) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/06/anaptysbio-inc-anab-rating-lowered-to-hold-at-zacks-investment-research.html.
In related news, major shareholder Holdings A/S Novo sold 491,294 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $21.12, for a total transaction of $10,376,129.28. Following the completion of the transaction, the insider now directly owns 2,952,527 shares of the company’s stock, valued at $62,357,370.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the firm’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,133,940 shares of company stock valued at $24,223,316.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Sphera Funds Management LTD. purchased a new position in AnaptysBio during the first quarter valued at $708,000. Perceptive Advisors LLC purchased a new position in AnaptysBio during the first quarter valued at $24,474,000. JPMorgan Chase & Co. purchased a new position in AnaptysBio during the first quarter valued at $3,851,000. Frazier Management LLC purchased a new position in AnaptysBio during the first quarter valued at $102,354,000. Finally, Monashee Investment Management LLC purchased a new position in AnaptysBio during the first quarter valued at $694,000. 71.35% of the stock is owned by institutional investors.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.